» Articles » PMID: 2454723

Surgery for Glioma Relapse. Factors That Influence a Favorable Outcome

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 1988 Jul 15
PMID 2454723
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The role of cytoreductive surgery alone as effective salvage therapy for immediate palliation and durable symptom-free remission was examined in 17 patients (six with astrocytoma, seven with anaplastic astrocytoma, and four with glioblastoma) who developed symptomatic tumor relapse after initial surgery and irradiation. Individuals with widely disseminated subependymal, bihemispheral, or brainstem involvement were excluded. After reoperation, patients with astrocytoma and anaplastic tumors have been observed for an average of 31 and 29 months, respectively. As of this writing, all 13 patients are alive without evidence of tumor progression. Three of the four patients with glioblastomas have died 5, 12, and 17 months after reoperation, respectively. The 14 surviving patients overall have a current average Karnofsky performance level of 95. The durability of surgically induced palliation alone, the safe limits of resectability, and the clinical features associated with a favorable surgical response have been examined. The results indicate that, in selected individuals, durable remissions can be achieved by adequate resection of symptomatic tumor mass.

Citing Articles

The role of cytoreductive surgery in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Ryken T, Kalkanis S, Buatti J, Olson J J Neurooncol. 2014; 118(3):479-88.

PMID: 24756348 DOI: 10.1007/s11060-013-1336-7.


Hypofractionated reirradiation for recurrent malignant glioma.

Henke G, Paulsen F, Steinbach J, Ganswindt U, Isijanov H, Kortmann R Strahlenther Onkol. 2009; 185(2):113-9.

PMID: 19240998 DOI: 10.1007/s00066-009-1969-9.


Cystemustine in recurrent high grade glioma.

Durando X, Thivat E, Roche H, Bay J, Lemaire J, Verrelle P J Neurooncol. 2006; 79(1):33-7.

PMID: 16575534 DOI: 10.1007/s11060-005-9096-7.


Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours.

Boiardi A, Eoli M, Salmaggi A, Zappacosta B, Fariselli L, Milanesi I J Neurooncol. 2002; 54(1):39-47.

PMID: 11763421 DOI: 10.1023/a:1012510513780.


Back to the future--radiotherapy in high grade gliomas.

Brada M Br J Cancer. 1989; 60(1):1-4.

PMID: 2679840 PMC: 2247338. DOI: 10.1038/bjc.1989.207.